Acorda Therapeutics appoints Board member John Kelley as Non-Executive Chair of its Board of Directors

– USA, NY –  Acorda Therapeutics, Inc. (NASDAQ: ACOR), today announced that its Board of Directors has elected John Kelley as the non-executive board Chair, effective November 25, 2019. Mr. Kelley has been a board member at Acorda since 2008.

“I am delighted that John will be chairing Acorda’s board,” said Ron Cohen, M.D., Acorda’s President and CEO. “John has extensive senior leadership and commercial experience in the biopharmaceutical industry, and we expect that he will enhance the board’s governance in his new role as Chair.”

About John Kelley

From 2013 until 2017, Mr. Kelley was the CEO of Tenax Therapeutics, Inc. a biotechnology company developing products for the critical care market; he was also a member of its board of directors. Previously he was the President, Chief Executive Officer and a director of Phyxius Pharma. From 2004 to 2009, Mr. Kelley was the President and Chief Operating Officer of The Medicines Company, a pharmaceutical company providing acute care hospital products worldwide. He was a member of their board of directors from 2005 to 2009.

“I’m honored to serve as Chair of the Acorda board,” said Mr. Kelley. “During my time as a director, Acorda has brought two important therapies to market – AMPYRA, which has become a standard of care to improve walking in people with multiple sclerosis, and most recently, INBRIJA for on-demand treatment of OFF periods by people with Parkinson’s disease. I believe that INBRIJA, likewise, will become a standard of care for those living with Parkinson’s, and am looking forward to continuing to work with the Board, Ron and Acorda’s leadership team to build value on behalf of all of the company’s stakeholders.”

He also held a number of senior-level positions at Aventis. Mr. Kelley received a B.A. from Wilkes University and an M.B.A. from Rockhurst University.

About Acorda Therapeutics

Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA is approved for intermittent treatment of OFF episodes in adults with Parkinson’s disease treated with carbidopa/levodopa. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor such as phenelzine or tranylcypromine within the last two weeks. INBRIJA utilizes Acorda’s innovative ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. Acorda also markets the branded AMPYRA Extended-Release Tablets, 10 mg.

For more information: http://www.acorda.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Comments are closed.